← Back to all trials
Recruiting
NCT06987214
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study
Conditions: Bronchiectasis Adult
Sex: All
Ages: 25 Years – 80 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 10
Sponsor: Ruijin Hospital
Location: Ruijin Hospital Hainan Branch, Shanghai Jiao Tong University School of Medicine Qionghai Hainan
Summary
This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis). The treatment involves harvesting bronchial basal layer stem cells from the patient, expanding them ex vivo, and reintroducing them via bronchoscopic infusion to repair damaged lung tissue.
Eligibility Criteria
Inclusion Criteria:
1. Age 25-80 years.
2. Confirmed diagnosis of bronchiectasis.
3. FEV1 ≥35% predicted; DLCO ≥30% and \
Source: ClinicalTrials.gov (NCT06987214). StuddyBuddy aggregates publicly available trial information.
